Patents by Inventor Laura POLIVKA

Laura POLIVKA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11389434
    Abstract: The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway in normal and abnormal human mast cells (MCs). These results prompt the inventors to explore the consequence of the inhibition of the HH pathway, especially the canonical pathway, on MC proliferation. They demonstrate that Hedgehog inhibitors inhibit proliferation and induces apoptosis of mast cells. Accordingly the present invention relates to a method of treating a mast cell disease in a patient in need there of comprising administering to the patient a therapeutically effective amount of a Hedgehog inhibitor.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 19, 2022
    Assignees: INSERM, FONDATION IMAGINE, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Leila Maouche-Chretien, Christine Bodemer, Olivier Hermine, Laura Polivka
  • Publication number: 20200108053
    Abstract: The inventors demonstrate for the first time the activation of the Hedgehog (HH) signaling pathway in normal and abnormal human mast cells (MCs). These results prompt the inventors to explore the consequence of the inhibition of the HH pathway, especially the canonical pathway, on MC proliferation. They demonstrate that Hedgehog inhibitors inhibit proliferation and induces apoptosis of mast cells. Accordingly the present invention relates to a method of treating a mast cell disease in a patient in need there of comprising administering to the patient a therapeutically effective amount of a Hedgehog inhibitor.
    Type: Application
    Filed: May 17, 2018
    Publication date: April 9, 2020
    Inventors: Leila MAOUCHE-CHRETIEN, Christine BODEMER, Olivier HERMINE, Laura POLIVKA
  • Publication number: 20190125826
    Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of inflammatory skin diseases associated with desmoglein-1 deficiency. The inventors show, for the first time, that the structural protein DSG1 directly acts as a novel and unexpected inhibitor of epithelial inflammation via the inhibition of NF-?B signaling pathway. In particular, the present invention relates to a method of treating an inflammatory skin disease associated with desmoglein-1 deficiency in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an agent capable of restoring the expression of desmogelin-1. Particularly, the inventors carried out the whole exome sequencing, histopathological, electron microscopy, immunofluorescence and immunological analyses in two unrelated patients presenting with SAMEC syndrome.
    Type: Application
    Filed: April 21, 2017
    Publication date: May 2, 2019
    Inventors: Christine BODEMER, Asma SMAHI, Elodie BAL, Laura POLIVKA, Smail HADJ-RABIA